BMJ Open
July 1, 2026
Kirsten Morley, Shalini Arunogiri, Katherine L. Mills et al.
INTRODUCTION: The treatment of comorbid post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) is significantly more challenging than the treatment of either disorder alone. While gold standard evidence-based treatments exist for this comorbidity, clinically significant improvements are only observed in approximately half of clinical trial participants. The use of adjunctive...
Psychosomatic Medicine and General Practice
June 30, 2026
Viacheslav Zaika, Yan Tytarenko
Background. Ketamine provides rapid but short-lived antidepressant effects for treatment-resistant depression (TRD). To prolong this response, ketamine-assisted therapy (KAT) combines the drug's pharmacological effects with psychotherapy. Aim. This study aims to analyze scientific evidence regarding the synergistic interaction between ketamine's pharmacological effects and modern...
Pharmacology, Biochemistry, and Behavior
June 30, 2026
Lucie Ladislavová, Viera Kútna, Kristýna Mazochová et al.
Psilocin (4-hydroxy-N, N-dimethyltryptamine) is a substituted tryptamine alkaloid and a nonselective serotonergic agonist acting predominantly at 5-HT2A/C receptors, with substantial binding to 5-HT1A and 5-HT2B receptors. Microdosing is the practice of taking a very small, sub-perceptual dose, typically 5% to 10% of a full recreational dose, to improve mood, creativity, and focus without...
PLoS One
June 29, 2026
Yunyun Zhao, Juanjuan Li, Xiaobei Li et al.
Objective: To evaluate the effects of mindfulness-based stress reduction (MBSR) combined with standard perioperative care on perioperative outcomes in patients with advanced hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). Methods: This retrospective study enrolled patients with advanced HCC who underwent TACE and received either standard perioperative care...
Healthcare
June 26, 2026
Sharmistha Roy, Amar Kanekar, Ashis Kumar Biswas et al.
Background/Objectives: University students commonly experience psychological distress driven by academic demands, social transitions, and financial pressures. Mindfulness-based interventions have emerged as scalable approaches to improve mental health. However, evidence comparing their effectiveness across delivery formats remains limited. This systematic review aimed to evaluate the...
Medicine
June 26, 2026
Ruixue Liu, Chunxiao Liu, Chunhui Li et al.
Dextromethorphan-bupropion, a novel oral N-methyl-D-aspartate receptor antagonist approved by the Food and Drug Administration in August 2022, launched in the United States in October 2022 for major depressive disorder. We aimed to detect and characterize the adverse events (AEs) of dextromethorphan-bupropion using the FDA adverse event reporting system from the 4th quarter of 2022 to the 4th...
Journal of Psychopharmacology
June 25, 2026
Joost C Van Mechelen, Tobias A Wieles, Laura Borghans et al.
Oral S-ketamine (S-KETPO) is being explored as an alternative to intravenous maintenance treatment (S-KETIV) in treatment-resistant depression (TRD). However, the first-pass effect with S-KETPO significantly alters S-ketamine's bioavailability and the systemic exposure of its active metabolites, raising potential safety and efficacy concerns. This study characterized the pharmacodynamic and...
Journal of Psychopharmacology
June 23, 2026
Lenka Seillier, Alexandre Seillier, Morgan A. Zvolska et al.
BACKGROUND: Major depressive disorder is one of the most debilitating psychiatric disorders worldwide. First-line treatments such as selective serotonin reuptake inhibitors have significant limitations, including delayed onset of therapeutic effects and treatment resistance in about 30% of patients. Increasing evidence suggests that acute administration of serotonergic psychedelics, such as...
Research Square
June 19, 2026
Aline Frick, Grace Blest‐hopley, Manesh Grin et al.
preprint
Abstract Rationale: Major depressive disorder (MDD) shows marked sex differences in prevalence, symptomatology, and treatment response. However, women remain underrepresented in many clinical trials, and sex-specific treatment outcomes are rarely examined. Objectives This study reanalyzed data from a randomized controlled trial comparing psilocybin and escitalopram for MDD to evaluate sex...
SAIMSARA Journal
June 15, 2026
This scoping review aims to comprehensively map and synthesize the breadth of evidence from original research on the relationship between psilocybin and health, spanning clinical trials, epidemiological surveys, mechanistic experiments, and cross-sectional attitudinal studies. The review uses 145 references and builds its evidence map from 216 original studies with 271241797 total...